Treatment of Post-Traumatic Stress Disorder (PTSD)
First-Line Psychotherapy Options
- The American College of Cardiology and VA/DoD Clinical Practice Guideline strongly recommends three specific trauma-focused psychotherapies, including Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR), with the strongest evidence base for treating PTSD 1, 2
- Prolonged Exposure (PE) demonstrates 40-87% of patients no longer meeting PTSD criteria after 9-15 sessions, according to the VA/DoD Clinical Practice Guideline 1, 2
- Cognitive Processing Therapy (CPT) is equally effective as exposure-based approaches and addresses negative trauma-related appraisals that fuel emotion dysregulation, as recommended by the VA/DoD Clinical Practice Guideline 1, 2
- Eye Movement Desensitization and Reprocessing (EMDR) provides comparable outcomes to PE and CPT, according to the VA/DoD Clinical Practice Guideline 1, 2
Critical Paradigm Shift: No Stabilization Phase Required
- The VA/DoD Clinical Practice Guideline recommends abandoning the traditional phase-based approach requiring prolonged stabilization before trauma processing, as it lacks empirical support 2, 3
- No randomized controlled trials demonstrate that patients with complex PTSD require or benefit from prolonged stabilization before trauma processing, according to the VA/DoD Clinical Practice Guideline 2
- Emotion dysregulation, dissociative symptoms, and self-loathing improve directly through trauma processing itself, without requiring separate stabilization interventions, as recommended by the VA/DoD Clinical Practice Guideline 1, 2
Pharmacotherapy: Second-Line or Adjunctive Treatment
- The VA/DoD Clinical Practice Guideline recommends considering medication when psychotherapy is unavailable, ineffective, the patient refuses psychotherapy, or residual symptoms persist after psychotherapy 1
- Sertraline, paroxetine, and venlafaxine are recommended as first-line medications for PTSD, with FDA approval for sertraline, according to the VA/DoD Clinical Practice Guideline 1
- Relapse rates are significantly higher after medication discontinuation (26-52%) compared to patients maintained on medication (5-16%), and substantially higher than relapse rates after completing trauma-focused psychotherapy, as reported by the VA/DoD Clinical Practice Guideline 1, 2
Treatment of Specific Symptoms
- Prazosin is strongly recommended (Level A evidence) for PTSD-related nightmares, with a starting dose of 1 mg at bedtime and an average effective dose of 3 mg, according to the VA/DoD Clinical Practice Guideline 1, 4
- Trazodone may be considered for sleep disturbances at 25-600 mg, though 60% experience side effects including daytime sedation, as reported by the VA/DoD Clinical Practice Guideline 1
Medications to AVOID
- The VA/DoD Clinical Practice Guideline strongly recommends against benzodiazepines for PTSD treatment, as evidence shows 63% of patients receiving benzodiazepines developed PTSD at 6 months compared to only 23% receiving placebo 1, 4
Treatment Algorithm
- The VA/DoD Clinical Practice Guideline recommends initiating trauma-focused psychotherapy immediately (PE, CPT, or EMDR) without delay, even in complex presentations 1, 2
- Adding or substituting pharmacotherapy is recommended if psychotherapy is unavailable, ineffective, or patient preference strongly favors medication, according to the VA/DoD Clinical Practice Guideline 1
Critical Pitfalls to Avoid
- The VA/DoD Clinical Practice Guideline recommends never using psychological debriefing (single-session intervention within 24-72 hours post-trauma), as randomized controlled trials show it may be harmful 1, 3, 4
- Delaying trauma-focused treatment by labeling patients as "too complex" is not recommended, as this assumption lacks empirical support and restricts access to effective interventions, according to the VA/DoD Clinical Practice Guideline 2
Treatment Duration and Maintenance
- Acute treatment typically consists of 9-15 sessions of trauma-focused psychotherapy, which is sufficient for 40-87% of patients to no longer meet PTSD criteria, as reported by the VA/DoD Clinical Practice Guideline 1, 2
- Maintenance pharmacotherapy should continue for 6-12 months minimum after symptom remission, as discontinuation leads to high relapse rates, according to the VA/DoD Clinical Practice Guideline 1